Red herring prospectus

Form S-4 Registration Statement for Proposed Merger of Net Element with Mullen Automotive is Declared Effective by the SEC

Retrieved on:

Tuesday, July 27, 2021

SEC filings, Financial markets, Initial public offering, U.S. Securities and Exchange Commission, Corporate finance, Shareholders, Prospectus, Registration statement, Proxy statement, Agencies of the United States government, Red herring prospectus, Regulation S-K

333-256166) (the Registration Statement) was declared effective by the U.S. Securities and Exchange Commission (the SEC) on July 26, 2021.

Key Points:

333-256166) (the Registration Statement) was declared effective by the U.S. Securities and Exchange Commission (the SEC) on July 26, 2021.
Net Element stockholders of record as of close of business on July 16, 2021 are entitled to vote at the Special Meeting.
The Registration Statement containing the proxy statement/prospectus/information statement is available through the SECs website atwww.sec.gov.
Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change.

AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter’s Option to Purchase Additional Shares

Retrieved on:

Tuesday, July 27, 2021

Initial public offering, Finance, Financial markets, Financial economics, U.S. Securities and Exchange Commission, Prospectus, Shelf registration, Registration statement, Stock market, Underwriting, Red herring prospectus, Regulation S-K

The gross proceeds to the Company, before deducting underwriting discounts and commissions and offering expenses, including the exercise in full of the underwriters option to purchase 1,363,636 additional shares of common stock, are approximately $5.75 million.

Key Points:

The gross proceeds to the Company, before deducting underwriting discounts and commissions and offering expenses, including the exercise in full of the underwriters option to purchase 1,363,636 additional shares of common stock, are approximately $5.75 million.
The shares of common stock were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No.
The offering of the shares of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical companyspecializingin the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases.

Absci Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on:

Monday, July 26, 2021

Financial markets, Finance, Money, Stock market, Corporate finance, Economy of New York City, NASDAQ, Stock, Ticker symbol, Underwriting, Red herring prospectus

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Absci were $230.0 million.

Key Points:

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Absci were $230.0 million.
Abscis common stock began trading on the Nasdaq Global Select Market on July 22, 2021, under the ticker symbol ABSI.
All shares in the offering were offered by Absci.
A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on July 21, 2021.

AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock

Retrieved on:

Thursday, July 22, 2021

Financial markets, Finance, Financial economics, Corporate finance, Stock market, Initial public offering, Actuarial science, Underwriting, Public offering, Stock, Greenshoe, Red herring prospectus

The Company has granted to the underwriter a 30-day option to purchase up to an additional 818,181 shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points:

The Company has granted to the underwriter a 30-day option to purchase up to an additional 818,181 shares of common stock at the public offering price, less underwriting discounts and commissions.
The gross proceeds to AzurRx, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriters option to purchase additional common stock, are expected to be approximately $3.0 million.
The shares of common stock are being offered by the Company pursuant to a shelf registration statement on Form S-3 (File No.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical companyspecializingin the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases.

TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million

Retrieved on:

Thursday, July 22, 2021

Financial markets, Finance, Financial economics, Stock market, Corporate finance, Initial public offering, Underwriting, Actuarial science, Stock, Public offering, Greenshoe, Red herring prospectus

In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 589,005 shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points:

In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 589,005 shares of common stock at the public offering price, less underwriting discounts and commissions.
The closing of the public offering is expected to occur on or about July 26, 2021, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.
The shares of common stock are being offered pursuant to an effective registration statement on Form S-3 (File No.

Absci Announces Pricing of Initial Public Offering

Retrieved on:

Thursday, July 22, 2021

Financial markets, Financial economics, Finance, Corporate finance, Initial public offering, Stock market, Underwriting, Stock, Public offering, Greenshoe, Red herring prospectus

VANCOUVER, Wash., July 21, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of $16.00 per share.

Key Points:

VANCOUVER, Wash., July 21, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of $16.00 per share.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Absci, are expected to be $200.0 million, excluding any exercise of the underwriters option to purchase additional shares.
The offering is expected to close on July 26, 2021, subject to the satisfaction of customary closing conditions.
In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock

Retrieved on:

Wednesday, July 21, 2021

Financial markets, Stock market, Finance, Financial economics, Corporate finance, Initial public offering, Actuarial science, Underwriting, Stock, Greenshoe, Red herring prospectus

In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional392,670 shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points:

In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional392,670 shares of common stock at the public offering price, less underwriting discounts and commissions.
The offering is expected to close on or about July 26, 2021, subject to satisfaction of customary closing conditions.
The gross proceeds of the offering are expected to be approximately $10 million, prior to deducting underwriting discounts, commissions and estimated offering expenses and excluding the exercise of the underwriters option to purchase additional shares.
The shares of common stock are being offered pursuant to an effective registration statement on Form S-3 (File No.

Preston Hollow Community Capital, Inc. Launches Initial Public Offering

Retrieved on:

Wednesday, July 21, 2021

Preston Hollow is offering 10,526,316 shares of Class A common stock to the public at an initial price between $18.00 and $20.00 per share.

Key Points:

Preston Hollow is offering 10,526,316 shares of Class A common stock to the public at an initial price between $18.00 and $20.00 per share.
Preston Hollow further intends to grant the underwriters the option to purchase up to 1,578,947 additional shares of Class A common stock from Preston Hollow at the initial public offering price, less the underwriting discount, within 30 days after the date of this prospectus.
A registration statement on Form S-1 relating to the proposed initial public offering has been filed with the SEC but has not yet become effective.
About Preston Hollow Community Capital, Inc.
Preston Hollow Community Capital, Inc. provides specialized impact financing solutions for projects of significant social and economic importance to local communities in the United States.

DISCO Announces Pricing of Initial Public Offering

Retrieved on:

Wednesday, July 21, 2021

Data management, Professional services, Legal, Technology, Software, Initial public offering, Financial economics, Financial markets, Finance, U.S. Securities and Exchange Commission, Stock market, Corporate finance, Prospectus, Registration statement, Security, Public offering, Red herring prospectus

CS Disco, Inc. (“DISCO”) today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at a price to the public of $32.00 per share. In addition, the underwriters have been granted a 30 day option to purchase up to an additional 500,000 shares of common stock from DISCO and up to an additional 200,000 shares of common stock from the selling stockholder named in the prospectus at the initial public offering price, less underwriting discounts and commissions. DISCO will not receive any proceeds from the sale of shares by the selling stockholder.

Key Points:

CS Disco, Inc. ( DISCO ) today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at a price to the public of $32.00 per share.
DISCO will not receive any proceeds from the sale of shares by the selling stockholder.
J.P. Morgan Securities LLC and BofA Securities Inc. are acting as lead book-running managers and representatives of the underwriters for the offering.
The offering will be made only by means of a prospectus forming part of the effective registration statement relating to the offering.

kdc/one Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering

Retrieved on:

Monday, July 12, 2021

Retail, Other Consumer, Consumer, Other Retail, Home Goods, Manufacturing, Other Manufacturing, Initial public offering, Finance, Financial services, Stock market, Prospectus, Goldman Sachs, Investment banking, Red herring prospectus

The number of common shares to be sold and the price range for the IPO have not yet been determined.

Key Points:

The number of common shares to be sold and the price range for the IPO have not yet been determined.
Goldman Sachs & Co. LLC, J.P. Morgan, UBS Investment Bank, and BMO Capital Markets are acting as lead book-running managers for the IPO.
A registration statement relating to the proposed IPO has been filed with the SEC but has not yet become effective.
Copies of the registration statement and preliminary prospectus may also be obtained, when available, on kdc/ones profile at www.sec.gov and www.sedar.com .